SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 9, 2026) - Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("ARS Pharmaceuticals" or the "Company") (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark. This caused Plaintiff and other shareholders to purchase ARS's securities at artificially inflated prices. On June 24, 2026, after the market closed, ARS published a press release announcing that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle, and that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, ARS's stock price fell $2.52, or 23.9%, to close at $8.02 per share on June 25, 2026, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding ARS Pharmaceuticals's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the ARS Pharmaceuticals class action, go to www.faruqilaw.com/[SPRY](/en/us/SPRY) or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . Follow us for updates on LinkedIn , on X , or on Facebook . Frequently Asked Questions (FAQ) for Investors Regarding the ARS Pharmaceuticals Securities Class Action Lawsuit: What is the ARS Pharmaceuticals securities fraud lawsuit about? A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased the company's securities during the Class Period. The complaint alleges that defendants made overwhelmingly positive statements to investors while simultaneously disseminating false and misleading statements and/or concealing material adverse facts regarding the expected timeline for expanded insurance coverage of neffy through CVS Caremark. Specifically, the lawsuit alleges that defendants failed to disclose that no new commercial formulary additions or coverage decisions would be issued for neffy in the July 1, 2026 cycle, and that CVS Care...